DRL to market and distribute Amgen’s Xgeva (denosumab), Vectibix (panitumumab) and Prolia (denosumab) in India

Dr Reddy’s Laboratories (DRL) has expanded its strategic collaboration with US-based independent biotechnology firm Amgen to market and distribute in India three of latter’s medicines, used in the therapy areas of oncology and osteoporosis.

Under the terms of collaboration, DRL will commercialise Xgeva (denosumab), Vectibix (panitumumab) and Prolia (denosumab) in India.

• Xgeva is a Rank ligand (RANKL) inhibitor and is approved in India for the prevention of skeletal related events in patients with advanced malignancies involving bone.
• Vectibix (panitumumab) is a cancer medication that interferes with the growth and spread of cancer cells in the body.
• Prolia is a Rank ligand inhibitor approved in India for treatment of post-menopausal women with osteoporosis at high risk for fracture and also for treatment of increased bone mass in men with osteoporosis.